Bristol-Myers Squibb (BMY) Competitors

Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Do insiders & institutionals have more ownership in BMY or JNJ?

76.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer BMY or JNJ?

In the previous week, Johnson & Johnson had 53 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 105 mentions for Johnson & Johnson and 52 mentions for Bristol-Myers Squibb. Bristol-Myers Squibb's average media sentiment score of 1.47 beat Johnson & Johnson's score of 1.22 indicating that Bristol-Myers Squibb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bristol-Myers Squibb	48 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Johnson & Johnson	80 Very Positive mention(s)	12 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Is BMY or JNJ a better dividend stock?

Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 4.1%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.0%. Bristol-Myers Squibb pays out -56.1% of its earnings in the form of a dividend. Johnson & Johnson pays out 74.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 17 consecutive years and Johnson & Johnson has raised its dividend for 63 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and lower payout ratio.

Does the MarketBeat Community believe in BMY or JNJ?

Johnson & Johnson received 34 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 66.10% of users gave Bristol-Myers Squibb an outperform vote while only 64.93% of users gave Johnson & Johnson an outperform vote.

Company	Underperform	Outperform
Bristol-Myers Squibb	Outperform Votes 1088 66.10%	Underperform Votes 558 33.90%
Johnson & Johnson	Outperform Votes 1122 64.93%	Underperform Votes 606 35.07%

Is BMY or JNJ more profitable?

Johnson & Johnson has a net margin of 18.20% compared to Bristol-Myers Squibb's net margin of -18.53%. Johnson & Johnson's return on equity of 34.24% beat Bristol-Myers Squibb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bristol-Myers Squibb	-18.53%	13.93%	2.46%
Johnson & Johnson	18.20%	34.24%	13.63%

Which has preferable earnings and valuation, BMY or JNJ?

Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol-Myers Squibb	$48.30B	2.57	-$8.95B	-$4.42	-13.84
Johnson & Johnson	$88.82B	4.45	$14.07B	$6.65	24.66

Do analysts rate BMY or JNJ?

Bristol-Myers Squibb currently has a consensus price target of $57.86, suggesting a potential downside of 5.40%. Johnson & Johnson has a consensus price target of $171.33, suggesting a potential upside of 4.46%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Bristol-Myers Squibb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol-Myers Squibb	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.32
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.56

Which has more risk & volatility, BMY or JNJ?

Bristol-Myers Squibb has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Summary

Johnson & Johnson beats Bristol-Myers Squibb on 16 of the 22 factors compared between the two stocks.